Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CLONAL HEMATOPOIETIC DISORDERS USING KINASE INHIBITORS
    Publication number: 20260306462
    Abstract: The present application provides methods for the treatment of clonal hematopoietic disorders using compounds that modulate kinase activity or antibodies that binds to human mutant calreticulin (CALR).
    Type: Application
    Filed: December 19, 2025
    Publication date: October 8, 2026
    Inventors: Ricardo Macarrón Larumbe, Ekaterine Asatiani, Hang Thi Dang, Brent Douty, Xin Li, Michael Liang, Patrick Mayes, Minh Nguyen, Evan Styduhar, Oleg Vechorkin, Anlai Wang, Xiaozhao Wang, Hai Fen Ye, Eddy W. Yue, Peng Zhao
  • KRAS INHIBITORS
    Publication number: 20260297084
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: February 27, 2025
    Publication date: October 1, 2026
    Inventors: Alexander Sokolsky, Peter Carlsen, Chunyin Marshall Law, Lei Liu, Rocco Policarpo, III, Xiaozhao Wang
  • FUSED BICYCLIC COMPOUNDS AS VRK1 INHIBITORS
    Publication number: 20260274842
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and methods of using the compounds for treatment of cancer and inhibiting VRK1, as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 13, 2026
    Publication date: September 17, 2026
    Inventors: Le Zhao, Yanran Ai, Huan Chen, Dipendu Das, Balu Dherange, Kelly Federowicz, Gia Hoang, Bin Hu, Javier A. Feliciano Leal, Yong Li, Leslie Brooke Epling McQuirter, Xiaozhao Wang, Eddy W. Yue, Guofeng Zhang
  • PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORS
    Publication number: 20260272918
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and methods of using the compounds for treatment of cancer and inhibiting VRK1, as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 13, 2026
    Publication date: September 17, 2026
    Inventors: Yong Li, Yanran Ai, Huan Chen, Kelly Federowicz, Yehao Qiu, Leslie Brooke Epling McQuirter, Cooper Ashley Taylor, Xiaozhao Wang, Eddy W. Yue, Guofeng Zhang, Le Zhao, Zhitong Zheng
  • PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORS
    Publication number: 20260274841
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and methods of using the compounds for treatment of cancer and inhibiting VRK1, as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 13, 2026
    Publication date: September 17, 2026
    Inventors: Huan Chen, Yanran Ai, Kelly Federowicz, Yong Li, Leslie Brooke Epling McQuirter, Cooper Ashley Taylor, Xiaozhao Wang, Eddy W. Yue, Guofeng Zhang, Le Zhao, Zhitong Zheng
  • Fused pyrazine derivatives as A2A / A2B inhibitors
    Patent number: 12735424
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: September 15, 2026
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • Tricyclic triazolo compounds as DGK inhibitors
    Patent number: 12692276
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: July 28, 2026
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang
  • FURANYL OR THIENYL PYRIMIDINES AS CDK4 INHIBITORS
    Publication number: 20260209246
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: January 23, 2026
    Publication date: July 23, 2026
    Inventors: Ming Xiang, Joshua Hummel, Yang Li, Dibyendu Mondal, Shaoqun Qian, Shicheng Shi, Xiaozhao Wang, Bo Wei
  • KRAS INHIBITORS
    Publication number: 20260158024
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 12, 2025
    Publication date: June 11, 2026
    Inventors: Alexander Sokolsky, Rocco Policarpo, III, Xiaozhao Wang, Wenhao Zhang, Wenyu Zhu, Suman Chakrabarty, Chengtsung Lai, Haolin Yin, Nathaniel Greenwood
  • 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS
    Publication number: 20260132122
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 6, 2025
    Publication date: May 14, 2026
    Inventors: Liana Hie, Joshua Hummel, Xiaolei Li, Sharada Manns, Dibyendu Mondal, Shaoqun Qian, Xiaozhao Wang, Bo Wei, Ming Xiang
  • PYRIMIDINE INDOLES AS CDK4 INHIBITORS
    Publication number: 20260125391
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 4, 2025
    Publication date: May 7, 2026
    Inventors: Peter Niels Carlson, Liana Hie, Joshua Hummel, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Eli Ortiz, Robert Susick, Xiaozhao Wang, Bo Wei
  • Tetracyclic compounds as DGK inhibitors
    Patent number: 12600722
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Tetracyclic compounds as DGK inhibitors
    Patent number: 12600723
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Tricyclic compounds as inhibitors of KRAS
    Patent number: 12600717
    Abstract: Disclosed are compounds of Formula I (shown below), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Zhiyong Yu, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao
  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20260098041
    Abstract: The present application is concerned with tricyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 26, 2025
    Publication date: April 9, 2026
    Applicant: Incyte Corporation
    Inventors: Le ZHAO, Yanran AI, Marc DELLER, Javier FELICIANO, Ananda GHOSH, Leslie McQUIRTER, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS
    Publication number: 20260070915
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 and 4 (CDK2 and CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Shicheng Shi, Joshua Hummel, Jacob J. Lacharity, Lei Liu, Eli Ortiz, Xiaozhao Wang, Bo Wei, Ming Xiang
  • SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS
    Publication number: 20260070914
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 and 4 (CDK2 and CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Yang Li, Joshua Hummel, Lei Liu, Shaoqun Qian, Xiaozhao Wang
  • KRAS INHIBITORS
    Publication number: 20260069605
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Alexander Sokolsky, Yannick Boni, Gia Hoang, Bin Hu, Gencheng Li, Rocco Policarpo, III, Brandon Smith, Xiaozhao Wang, Michael Witten, Wenhao Zhang, Suman Chakrabarty
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20260042765
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: July 15, 2025
    Publication date: February 12, 2026
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • KRAS INHIBITORS
    Publication number: 20260034126
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 30, 2025
    Publication date: February 5, 2026
    Inventors: Alexander Sokolsky, Suman Chakrabarty, Bin Hu, Rocco Policarpo, III, Brandon R. Smith, Xiaozhao Wang, Michael R. Witten, Wenhao Zhang, Wenyu Zhu, Chunyin Marshall Law, Haolin Yin